Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares ("ADS")

Related Keywords

Sweden ,Stockholm ,Japan ,United States ,American ,Japanese ,Swedish ,Dale Raine ,Victor Kastensson ,Stiftelsen Industrifonden ,Asahi Kasei ,Elmar Schnee ,Asahi Kasei Corporation ,Company Annual Report On Form ,Draft Press ,Global Co ,Opinion Committee Of Lazard ,Securities Exchange ,Lazard ,Calliditas Therapeutics ,American Depositary Shares ,Nasdaq Stockholm ,Securities Exchange Act ,Kasei Corporation ,Nasdaq Global Select Market ,Advokatfirman Vinge ,Calliditas Shares ,Irrevocable Undertakings ,Takeover Rules ,Annual Report ,Abuse Regulation ,Calliditas Common Shares ,Calliditas Common Share ,Draft Press Release ,Opinion Committee ,Lazard Nordics ,Sveriges Riksbank ,Ihr Portfolio ,